Search
for
Sort by
Research 511–540 of 1000+
- Next-Gen Therapeutics for Skin Cancer: Nutraceuticals
- Potential Consequences of the Use of Adipose-Derived Stem Cells in the Treatment of Hepatocellular Carcinoma
- Green Nanodrugs: Research Progress and Challenges of Plant-Derived Nanovesicles in Tumor Treatment
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Ursolic acid reduces prostate size and dihydrotestosterone level in a rat model of benign prostatic hyperplasia
- Heavy metals in biological samples of cancer patients: a systematic literature review
- Hypoactive Sexual Desire and Other Sexual Dysfunctions Caused by Side Effects of Medicines Used to Treat Various Somatic Diseases and for Contraception
- Total prostate volume as risk factor for semen pathologies in ageing male
- Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
- Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies
- Emerging medication for the treatment of male hypogonadism
- Evaluation and Treatment of Gender Dysphoria to Prepare for Gender Confirmation Surgery
- Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study
- Endocrine treatment of benign prostatichypertrophy: Current concepts
- UTILIZAÇÃO DE FINASTERIDA NO TRATAMENTO DA HIPERPLASIA PROSTÁTICA BENIGNA – RELATO DE CASO
- Efecto en el sangrado perioperatorio durante la resección transuretral de la próstata tras un mes de tratamiento con dutasteride
- 12 Treatment of hirsutism with 5α-reductase inhibitors
- Hair disorders in patients with cancer
- Runx1 Role in Epithelial and Cancer Cell Proliferation Implicates Lipid Metabolism and Scd1 and Soat1 Activity
- Epigenetic regulation in adult stem cells and cancers
- TREATMENT PEARLS FROM EUROPE
- Prevalence and Partern of Early Adverse Reactions in Cancer Patients Receiving Chemotherapy at Ocean Road Cancer Institute
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- Combinatorial Therapy of Letrozole- and Quercetin-Loaded Spanlastics for Enhanced Cytotoxicity against MCF-7 Breast Cancer Cells
- Exploring the relationship between anastasis and mitochondrial ROS-mediated ferroptosis in metastatic chemoresistant cancers: a call for investigation
- Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview
- Perspectives in dermatopathology: telomeres and telomerase in ageing and cancer; with emphasis on cutaneous disease
- Combined oral contraceptives promote androgen receptor and oestrogen receptor alpha upregulation in the female prostate (Skene’s paraurethral glands) of adult gerbils (Meriones unguiculatus)
- Repositioning Old Drugs for New Battles: The Expanding Role of Drug Repurposing in Cancer, Inflammation, and Metabolic Disease.